Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma

Abstract

Serum levels of tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in serum, the presence or absence of skeletal metastases, tumor grade, patient age, and erythrocyte sedimentation rate (ESR) were determined in 50 patients with prostatic adenocarcinoma before onset of any therapy. Crude survival rates were estimated for a 5-year period after the time of diagnosis. The prognostic value was estimated by means of the log rank test and multivariate life table analysis. The TPA, PAP, tumor stage, and ESR all appeared to be useful as prognostic markers. Tumor grade and patient age were not significantly related to crude survival. The TPA proved to be the most reliable prognostic marker in single test estimates as well as in a multivariate life table analysis (p less than 0.01).

Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas

“…Severeal studies have shown the prognostic value of the serum level of deoxythymidine kinase (S-TK) in nonHodgkdn lymphomas (NHL) (Ellims et al, 1981;Gronowitz et al, 1983;Hagberg et al, 1984a;Martinsson et al, 1988;Rehn et al, 1991) and in other tumour types such as Hodgkin's disease (Eriksson et al, 1985), acute non-lymphoblastic leukaemia (Archimbaud et al, 1988), small-cell lung cancer (Gronowitz et al, 1986;van der Gaast et al, 1991), multiple myeloma (Simonsson et al, 1988;Luoni et al, 1991), adenocarcinoma of the breast (Romain et al, 1990) and prostatic adenocarcinoma (Lewenhaupt et al, 1990). In NHL, the S-TK level has in several studies been the strongest prognostic factor when compared with other serum markers, proliferation-associated parameters and clinical variables (Hagberg et al, 1984a;Martnsson et al, 1988;Rehn et al, 1991).…”